Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus | Zendy

Christopher McGuigan | Zendy; Ranjith Pathirana | Zendy; Marco Migliore | Zendy; Rina Adak | Zendy; G Luoni | Zendy; Arwyn T. Jones | Zendy; Alberto DiezTorrubia | Zendy; MaríaJosé Camarasa | Zendy; Sonsoles Velázquez | Zendy; Geoffrey Henson | Zendy; Erik Verbeken | Zendy; Rebecca Sienaert | Zendy; Lieve Naesens | Zendy; Robert Snoeck | Zendy; Graciela Andreï | Zendy; Jan Balzarini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

Author(s) -

Christopher McGuigan,

Ranjith Pathirana,

Marco Migliore,

Rina Adak,

G Luoni,

Arwyn T. Jones,

Alberto DiezTorrubia,

MaríaJosé Camarasa,

Sonsoles Velázquez,

Geoffrey Henson,

Erik Verbeken,

Rebecca Sienaert,

Lieve Naesens,

Robert Snoeck,

Graciela Andreï,

Jan Balzarini

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm376

Subject(s) - varicella zoster virus , pharmacokinetics , bioavailability , in vivo , pharmacology , virus , nucleoside , drug , nucleoside analogue , chemistry , virology , biology , biochemistry , microbiology and biotechnology

To progress the anti-varicella-zoster-virus (VZV) aryl bicyclic nucleoside analogues (BCNAs) to the point of Phase 1 clinical trial for herpes zoster.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research